SILVER SPRING, Md., April 4, 2013 /PRNewswire/ -- Pharmagen, Inc. (OTCBB: PHRX) (the “Company” or “Pharmagen”) is excited to announce that it will be presenting its strategic vision on solving the nation’s drug shortage crisis to the North Carolina General Assembly at the North Carolina Biosciences Organization (NCBIO) Legislative Breakfast on April 16th. Each year, NCBIO brings together members of the General Assembly to enjoy breakfast with NCBIO members. This invite-only, legislative event will give Pharmagen the opportunity to meet with State Representatives and State Senators to discuss its planned move to North Carolina. RTI International and Kymanox both event sponsors are North Carolina companies integral to implementing the Pharmagen manufacturing strategy.
About Pharmagen
Pharmagen, Inc. (“Pharmagen”), and wholly owned subsidiaries and operating divisions Pharmagen Laboratories, Inc., Pharmagen Distribution, LLC and Pharmagen Nutraceuticals, Inc. is the leader in innovative solutions to the nation’s sterile pharmaceutical crisis. With a multifaceted approach, Pharmagen is meeting the demand of health provider market through dynamic, independent wholesale, compounding, and innovative IT solutions. Nationally focused, Pharmagen is a dynamic distributor of specialty drugs, compounding and admix pharmacy and producer of over-the-counter (“OTC”) branded multivitamins to the healthcare provider market. Pharmagen currently functions as a just-in-time source of supply for hospitals for those products that are hard-to-find due to drug manufacturers’ production shortages.
About NCBIO
NCBIO is dedicated to promoting the future growth and development of North Carolina‘s bioscience industry. NCBIO advocates for state and federal public policies that encourage the growth of life science companies, support the development of a strong life science workforce, and promote research and technology transfer at universities and other institutions. The Organization also provides members opportunities to network, collaborate and save money. NCBIO’s ultimate goal is to help North Carolina‘s bioscience community fulfill its extraordinary promise as a source of economic opportunity and improved quality of life for citizens of North Carolina and people around the world.
About RTI International
RTI International is one of the world’s leading research institutes, dedicated to improving the human condition by turning knowledge into practice. Our staff of more than 3,700 provides research and technical services to governments and businesses in more than 75 countries in the areas of health and pharmaceuticals, education and training, surveys and statistics, advanced technology, international development, economic and social policy, energy and the environment, and laboratory testing and chemical analysis.
About Kymanox
Kymanox, with headquarters now in RTP, NC, is a premier technical products and technical project management company. We are experts in providing our clients in the Biopharmaceutical, Medical Device, and Nanotechnology industries with engineering, scientific, regulatory, and process operations support. Our engineers solve complex scale-up and manufacturing problems and our compliance team ensures products receive FDA and global regulatory approval. With our competency and focus on commercialization, Kymanox helps bring new products to patients in need.
Contact: 888-264-4597 or info@pharmagenrx.com
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “forecast”, “anticipate”, “estimate”, “project”, “intend”, “expect”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pharmagen actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pharmagen’ filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pharmagen herein are expressly qualified in their entirety by the above-mentioned.
SOURCE Pharmagen, Inc.
